First-ever covalent irreversible inhibition of a protease central to hepatitis C infection
Monday, November 29, 2010 - 03:20
in Biology & Nature
WALTHAM, MA -- November 28, 2010 -- Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the...